Leading Companies

Non-Invasive Cancer Diagnostics Market – Competitive Landscape

Some of the key players operating in the global non-invasive cancer diagnostics market include Roche Diagnostics, Hologic Inc., Qiagen, Gen-Probe Inc., Digene Corporation, Abbott Molecular, IVDiagnostics, Laboratory Corporation of America Holdings, OncoCyte Corporation, Arquer Diagnostics Ltd. and Affymetrix Inc.

Increasing product launches as a part of organic strategies to rule the market is also the key factor contributing to the non-invasive cancer diagnostics market growth. For instance, in March 2019, NeoGenomics Laboratories Inc. announced the launch of Ventana PD-L1 (SP142) Assay for tumor tissue testing in patients with a triple negative subtype of breast cancer. The test is approved by the US FDA for patients who might respond to TECENTRIQ, an immune checkpoint inhibitor in combination with chemotherapy.

Further, in 2016, Exosome Diagnostics, Inc. launched ExoDx Prostate (IntelliScore) test. The test uses genetic information from urine sample to evaluate patient risk for high grade prostate cancer.

In 2016, Laboratory Corporation of America Holdings, launched Epi proColon, the first FDA-approved DNA based blood test for colorectal cancer screening with FDA approval.

The inorganic strategies by market players are continuously boosting the non-invasive cancer diagnostics market. For instance, For instance, in November 2018, Belgian molecular diagnostics company, Biocartis Group entered into an agreement with AstraZeneca for development of lung cancer molecular diagnostic biomarker.

In 2017, Lonza, a biopharmaceutical development and manufacturing company, acquired HanaBioMaed Life Sciences OU, a company dedicated to research and development, manufacturing and distribution of products for the exosome genome market. Through this acquisition, company will invest to develop exosome-based early-stage cancer screening and molecular diagnostic tests. In same year, CORE Diagnostics partnered with CellMax Life to introduce CellMax’s genetic cancer risk test and ctDNA-based liquid biopsy throughout India.